<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4423596&amp;fmt=gif">
Discover AGCellerate™ for LVV - a faster option to get your GMP-ready lentiviral vector product   Learn about AGCellerate

The Future of Plug-and-Play Large-Scale AAV Manufacturing​


Adeno-associated viral vectors (AAV) offer a key component in cell and gene therapy treatments. In fact, the American Society of Cell & Gene Therapy published a study that found 89% of gene therapy in clinical trials uses Viral Vector for delivery, with AAV being the most commonly used vector type.

However, there is a lack of standardization in our industry for AAV manufacturing, which can impact your product timelines and its ability to reach clinical and commercial phases. A need for platforms that meet any vector project type is becoming a necessity. 

In this on-demand webinar, we explore the potential of "Plug-and-Play" AAV manufacturing platforms and important considerations for finding the best outsourcing partner to produce your viral vector materials. 

Access this webinar to learn more about the promise of viral vector production and manufacturing that can meet any need. 

AGC Logo_RGB_Icon


 Watch the webinar now